Van Tornout J - Search Results

1

Corbeel L, Van den Berghe G, Jaeken J, Van Tornout J, Eeckels R. Corbeel L, et al. Among authors: van den berghe g, van tornout j. Eur J Pediatr. 1985 Mar;143(4):284-90. doi: 10.1007/BF00442302. Eur J Pediatr. 1985. PMID: 3987728

2

Prematurity and hepatoblastoma: more than just an association?

Feusner J, Buckley J, Robison L, Ross J, Van Tornout J. Feusner J, et al. Among authors: van tornout j. J Pediatr. 1998 Oct;133(4):585-6. doi: 10.1016/s0022-3476(98)70084-8. J Pediatr. 1998. PMID: 9787710 No abstract available.

3

Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group.

Van Tornout JM, Buckley JD, Quinn JJ, Feusner JH, Krailo MD, King DR, Hammond GD, Ortega JA. Van Tornout JM, et al. J Clin Oncol. 1997 Mar;15(3):1190-7. doi: 10.1200/JCO.1997.15.3.1190. J Clin Oncol. 1997. PMID: 9060563

4

Melanotic neuroectodermal tumor of infancy. A case report of paratesticular primary with lymph node involvement.

De Chiara A, Van Tornout JM, Hachitanda Y, Ortega JA, Shimada H. De Chiara A, et al. Among authors: van tornout jm. Am J Pediatr Hematol Oncol. 1992 Nov;14(4):356-60. doi: 10.1097/00043426-199211000-00014. Am J Pediatr Hematol Oncol. 1992. PMID: 1333732

5

Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC.

Van Tornout JM, Spruck CH 3rd, Shibata A, Schmutte C, Gonzalez-Zulueta M, Nichols PW, Chandrasoma PT, Yu MC, Jones PA. Van Tornout JM, et al. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):493-7. Cancer Epidemiol Biomarkers Prev. 1997. PMID: 9232335

6

Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Gonzalez-Zulueta M, et al. Among authors: van tornout jm. Cancer Res. 1995 Oct 15;55(20):4531-5. Cancer Res. 1995. PMID: 7553622

7

Association of collagen type 1 alpha1 gene polymorphism with bone density in early childhood.

Sainz J, Van Tornout JM, Sayre J, Kaufman F, Gilsanz V. Sainz J, et al. Among authors: van tornout jm. J Clin Endocrinol Metab. 1999 Mar;84(3):853-5. doi: 10.1210/jcem.84.3.5575. J Clin Endocrinol Metab. 1999. PMID: 10084560

8

Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent.

Sainz J, Van Tornout JM, Loro ML, Sayre J, Roe TF, Gilsanz V. Sainz J, et al. Among authors: van tornout jm. N Engl J Med. 1997 Jul 10;337(2):77-82. doi: 10.1056/NEJM199707103370202. N Engl J Med. 1997. PMID: 9211676 Free article.

9

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. Hanna GJ, et al. Among authors: van tornout jm. Clin Cancer Res. 2023 Nov 14;29(22):4555-4563. doi: 10.1158/1078-0432.CCR-23-1030. Clin Cancer Res. 2023. PMID: 37643133 Free PMC article. Clinical Trial.

10

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

Jang S, Strickland B, Finis L, Kooijman JJ, Melis JJTM, Zaman GJR, Van Tornout J. Jang S, et al. Among authors: van tornout j. Cancer Chemother Pharmacol. 2023 Jun;91(6):491-499. doi: 10.1007/s00280-023-04534-7. Epub 2023 May 6. Cancer Chemother Pharmacol. 2023. PMID: 37148323 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page